RxDoctor Payments Data

Richard Robertson, MD

Interventional Pain Medicine · Covington, LANPI 1053756965

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,786 of the $5,801 with a category attached, or 65.3%. 20 manufacturers reported payments, led by Biotronik NRO, Inc. at 40.2% of the total. 2025 is the largest year on record at $3,058, 3.2 times the $948 reported in 2019.

$5,801in general payments, 2019–2025

Across 125 payments — averaging $46.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik NRO, Inc.$2K
  • Abbott$1K
  • Globus Medical$676
  • Boston Scientific$555
  • Vertiflex, Inc.$199
  • SPR Therapeutics, Inc$186
  • plus $764 from 14 others

What the payments were for

  • Travel & lodging$2,01635%
  • Food & beverage$3,78665%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,801 in reported general payments places this provider in the 55th percentile of 57 interventional pain medicine providers in Louisiana.

See all interventional pain medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$267,852
Medicare patients
513
Services billed
3,433

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen1,466$45,895
BelbucaBuprenorphine Hcl49$43,931
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,653$35,706
Xtampza ErOxycodone Myristate40$26,961
Gabapentin809$10,744
Pregabalin742$7,765
Oxycodone Hcl364$7,226
Buprenorphine28$5,280
MovantikNaloxegol Oxalate11$4,349
Tizanidine Hcl393$3,949
Morphine Sulfate ErMorphine Sulfate136$3,931
Tramadol Hcl483$3,834
Fentanyl41$3,706
Lidocaine20$2,506
Hydromorphone Hcl92$1,721

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$86$70,89289 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 57 interventional pain medicine providers in Louisiana.

Other interventional pain medicine in Covington

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →